# Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

> **NCT05629065** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 800 (estimated)

## Conditions studied

- Breast Cancer
- Gastrointestinal Cancer
- Gynecologic Cancer
- Thoracic Cancer
- Genitourinary Cancer

## Interventions

- **OTHER:** Clinician Nudge Email
- **OTHER:** Patient Nudge Letter and Share questionaire

## Key facts

- **NCT ID:** NCT05629065
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-28
- **Primary completion:** 2024-09-30
- **Final completion:** 2028-06
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629065, "Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05629065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*